Phillip Pang, M.D., Ph.D.

Phillip Pang, M.D., Ph.D.

Former Executive Vice President, Chief Medical Officer and Interim Head of ResearchatVir Biotechnology· In proxies 2021–2023

Pay in FY2023-10% from the year before · Vir Biotechnology stock -60.3% the same year

Phillip Pang, M.D., Ph.D. was paid $4.0M in FY2023 (Dec), down 10%. Vir Biotechnology stock fell 60.3% that year.

Pay$100 in the stock at the end of FY20 → $38
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vir BiotechnologyPublic company · 5 yr
    • Former Executive Vice President, Chief Medical Officer and Interim Head of Research2021 – Present · 5 yrStock in role -60%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?